Across TCGA pan-cancer cohorts, SLC25A5P7 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC25A5P7 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in acute myeloid leukemia (LAML), where higher SLC25A5P7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A5P7 expression acts as an unfavorable survival marker.
LAML are the cancer types where SLC25A5P7 Mutation most reproducibly stratifies survival.